25Oct 2021
Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Transcriptomics from a Phase 2a Randomized, Multicenter Double‐Blinded Study

Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Transcriptomics from a Phase 2a Randomized, Multicenter Double‐Blinded Study

Bimekizumab is a monoclonal antibody that selectively inhibits both IL‐17A and IL‐17F, currently under investigation for moderate to severe plaque psoriasis. Maintenance dosing every 4 weeks is well‐established with IL‐17 inhibitors in psoriasis. To investigate the possible dosing interval during bimekizumab maintenance therapy to maintain clear skin, to inform phase 3 studies. 49 patients with moderate to severe plaque psoriasis received bimekizumab 320 mg at Weeks 0/4, followed by bimekizumab 320 mg (N=17) or placebo (N=32) at Week 16. Efficacy, safety, pharmacokinetics, immunogenicity, and biopsy transcriptomic analyses were assessed to Week 28...

  • #dermatology

Like

Save

Share